Cefoperazone therapy of serious infections.
Cefoperazone was evaluated as the therapeutic agent in 64 adults with serious infections. Included were pneumonias, urinary tract infections, septicemia, osteomyelitis, joint infections, and superficial infections. A total of 84 organisms, including many multiantibiotic-resistant strains, were designated as the etiological agents. In most patients therapy was initiated before information on cefoperazone sensitivity of the infecting organism was available. This proved suitable in most instances. Clinical response to therapy was excellent in these individuals. Bacteriological responses coincided with the problems of the patient but did not reflect inadequacy of the antibacterial effect of cefoperazone. Adverse effects on renal function, including already impaired function, were not observed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002438:Cefoperazone; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000382:microbiology
D002511:Cephalosporins; D002438:Cefoperazone